15
Participants
Start Date
July 31, 2010
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2010
crizotinib
Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
rifampin
Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
crizotinib
Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
Pfizer Investigational Site, South Miami
Lead Sponsor
Pfizer
INDUSTRY